Results 211 to 220 of about 303,574 (253)
Some of the next articles are maybe not open access.
Current Opinion in Oncology, 1997
This review covers the literature on significant studies of small molecule inhibitors of the epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), Flk-1, and src family tyrosine kinases from 1996 through mid-1997. During this period, there has been substantial progress in the
W D, Klohs, D W, Fry, A J, Kraker
openaire +2 more sources
This review covers the literature on significant studies of small molecule inhibitors of the epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), Flk-1, and src family tyrosine kinases from 1996 through mid-1997. During this period, there has been substantial progress in the
W D, Klohs, D W, Fry, A J, Kraker
openaire +2 more sources
Neoadjuvant Tyrosine Kinase Inhibitors
Thoracic Surgery ClinicsNeoadjuvant tyrosine kinase inhibitor (TKI) therapy has appeal given the potential for early systemic disease control and tumor downstaging prior to surgery. Until recently, data has have come from smaller series with outcomes from larger trials, including NeoADAURA, ALNEO, and NAUTIKA1, reporting early results. Neoadjuvant use of TKI has been shown to
Gavitt A, Woodard +2 more
openaire +2 more sources
Tyrosine kinase inhibitors and the thyroid
Best Practice & Research Clinical Endocrinology & Metabolism, 2009Protein tyrosine kinase inhibitors (TKIs) have emerged as significant targets for novel cancer therapies. For patients with differentiated or medullary carcinomas unresponsive to conventional treatments, multiple novel therapies primarily targeting angiogenesis have entered clinical trials.
openaire +2 more sources
Inhibitors of protein tyrosine kinases
Current Opinion in Biotechnology, 1995The description in the past year of several novel protein tyrosine kinase inhibitors, which exhibit dramatic improvements in potency and specificity over earlier agents, will be considered a major turning point in the field. These compounds appear to have the necessary pharmacological properties to finally allow clarification of whether suppression of ...
D W, Fry, A J, Bridges
openaire +2 more sources
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
Lancet, The, 2007, Suzanne George, Jayesh Desai
exaly
CNS demyelination after initiating the tyrosine kinase inhibitor imatinib: A report of two cases
Multiple Sclerosis Journal, 2020, Xavier Montalbán, Dalia Rotstein
exaly